Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2100, Denmark.
Department of Biomedical and Pharmaceutical Sciences, Center for Structural and Functional Neuroscience, and Center for Biomolecular Structure and Dynamics, University of Montana, Missoula, Montana 59812, United States.
ACS Chem Neurosci. 2020 Mar 4;11(5):674-701. doi: 10.1021/acschemneuro.0c00003. Epub 2020 Feb 17.
Competitive antagonists for ionotropic glutamate receptors (iGluRs) are highly valuable tool compounds for studying health and disease states in the central nervous system. However, only few subtype selective tool compounds are available and the discovery of antagonists with novel iGluR subtype selectivity profiles remains a profound challenge. In this paper, we report an elaborate structure-activity relationship (SAR) study of the parental scaffold 2,3--3-carboxy-3-phenyl-proline by the synthesis of 40 new analogues. Three synthetic strategies were employed with two new strategies of which one being a highly efficient and fully enantioselective strategy based on C(sp3)-H activation methodology. The SAR study led to the conclusion that selectivity for the NMDA receptors was a general trend when adding substituents in the 5'-position. Selective NMDA receptor antagonists were obtained with high potency (IC values as low as 200 nM) and 3-34-fold preference for GluN1/GluN2A over GluN1/GluN2B-D NMDA receptors.
离子型谷氨酸受体(iGluRs)的竞争性拮抗剂是研究中枢神经系统健康和疾病状态的极具价值的工具化合物。然而,目前可用的亚型选择性工具化合物数量有限,因此发现具有新型 iGluR 亚型选择性特征的拮抗剂仍然是一个巨大的挑战。在本文中,我们通过合成 40 个新的类似物,对母体支架 2,3--3-羧基-3-苯基-脯氨酸进行了详细的构效关系(SAR)研究。采用了三种合成策略,其中两种是基于 C(sp3)-H 活化方法的高效、全对映选择性策略。SAR 研究得出的结论是,在 5'-位添加取代基通常会导致对 NMDA 受体的选择性。通过添加取代基,获得了具有高活性(IC 值低至 200 nM)和对 GluN1/GluN2A 相对于 GluN1/GluN2B-D NMDA 受体 3-34 倍选择性的选择性 NMDA 受体拮抗剂。